Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such
as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Colony-stimulating factors, such as
pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral
blood and may help the immune system recover from the side effects of chemotherapy. Giving
rituximab and cyclophosphamide together with pegfilgrastim may be effective in treating
leukemia or non-Hodgkin's lymphoma.
PURPOSE: This phase II trial is studying how well giving rituximab and cyclophosphamide
together with pegfilgrastim works in treating patients with B-cell leukemia, low-grade
non-Hodgkin's lymphoma, or mantle cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins